Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17085273 | 0.96 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1TSHRTHRB | |
| SCHEMBL17085275 | 0.92 | CYP4F2 (0.38) | CYP4F2CYP4A11ALDH1A1TSHRTHRB | |
| SCHEMBL16368797 | 0.85 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1TSHRTHRB | |
| SCHEMBL17756696 | 0.84 | CYP4F2 (0.60) | CYP4F2CYP4A11ALDH1A1TSHRTHRB | |
| SCHEMBL17756706 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11ALDH1A1TSHRTHRB | |
| SCHEMBL17756704 | 0.83 | CYP4F2 (0.63) | CYP4F2CYP4A11ALDH1A1TSHRTHRB | |
| SCHEMBL17756705 | 0.83 | CYP4F2 (0.63) | CYP4F2CYP4A11ALDH1A1TSHRTHRB | |
| SCHEMBL9481795 | 0.81 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1TSHRTP53 | |
| SCHEMBL16368808 | 0.81 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1TSHRTP53 | |
| SCHEMBL17085255 | 0.81 | ALDH1A1 (0.38) | CYP4F2CYP4A11ALDH1A1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855340-B2 | Hydrogel prodrugs | ASCENDIS PHARMA A/S (DK) | 2018-01-02 | — | — | US | disclosed |
| US-20160296600-A1 | Relaxin Prodrugs | ASCENDIS PHARMA RELAXIN DIVISION A/S (DK) | 2016-10-13 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ASCENDIS PHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150258205-A1 | Hydrogel Prodrugs | ASCENDIS PHARMA GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ADAMTS13, ADAMTS5, TNF | CYP4F2 958/4885CYP4A11 570/4885ALDH1A1 712/4885 |
| US-20160296600-A1 | Relaxin Prodrugs | RXFP1, RXFP2, RXFP3 | CYP4F2 2259/4885CYP4A11 1376/4885ALDH1A1 3629/4885 |
| US-20150258205-A1 | Hydrogel Prodrugs | CD44, DNPH1, PHYKPL | CYP4F2 946/4885CYP4A11 708/4885ALDH1A1 282/4885 |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | PTMS, PGLS, PAM | CYP4F2 975/4885CYP4A11 1109/4885ALDH1A1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.